Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P41180

UPID:
CASR_HUMAN

ALTERNATIVE NAMES:
Parathyroid cell calcium-sensing receptor 1

ALTERNATIVE UPACC:
P41180; Q13912; Q16108; Q16109; Q16110; Q16379; Q2M1T0; Q4PJ19

BACKGROUND:
The Extracellular calcium-sensing receptor plays a crucial role in calcium homeostasis by sensing changes in extracellular calcium levels. It modulates parathyroid hormone production through a G-protein-coupled mechanism, requiring both aromatic amino acids and divalent cations for full activation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the Extracellular calcium-sensing receptor could open doors to potential therapeutic strategies for managing disorders like familial Hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism, highlighting its significance in drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.